Broadly neutralizing antibodies are being considered for treatment and prevention of HIV-1. They are antibodies that target one or other of the HIV envelope proteins. A number have been developed
What I learned from this session was how little I currently know! I left the session a bit more knowledgeable but the task presented to Professor Cameron would require a short course rather than a 45 minute lecture. I understood things at the start but was soon lost. Not his fault
One can't come to a conference about HIV in Asia and Pacific without appreciating how lucky we are in Australia. It's more than just having the financial resources. We do have a comparatively inclusive society. We do have a good health system. GPs are involved in HIV care which places us well to manage the issues beyond the HIV virus.
Poster 60 - This poster reports on a supervised exercise program on physical health and quality of life in people living with HIV in Hong Kong.
The first day of the APACC 2018 for an Australian participant highlights the challenges we face in the Asia and Pacific region. As a first-time HIV conference attendee and low-caseload HIV prescriber, I was worried I wouldn't be able to follow the science and intricate complexities of antiretroviral prescribing. I didn't need to be concerned. The message was that we need to progress more at a political and social level to "End HIV" in our region. We have enough evidence in the basic science of HIV and therapeutics. We don't need more statistics to get it done. We need a greater understanding of social science.
I noted a poster on treatment of anorectal chlamydia in MSM in Japan (Mizushima D et al). In Australia, the use of single dose of azithromycin is questioned based on retrospective studies of its effectiveness. This prospective study followed 125 MSM with and without HIV with transcription mediated amplication confirmed anal chlamydia. They were all given AZM 1gm as a single dose and then a test of cure at 3 weeks. If they failed the test of cure they were given Doxy 200mg daily for a week and tested again 3 weeks later. Of the 118 MSM treated (7 dropped out) 87% were cured by AZM. Of the the 15 who failed to AZM treatment 12 were treated (3 dropped out) with Doxy and they were all cured.
There was no difference in effectiveness of AZM between HIV infected (97) and not HIV infected (21) in responding to AZM
Thoughts from the first day of the conference.